Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Selective inhibitors of phosphodiesterase type 5 prevent the breakdown of cyclic guanosine monophosphate resulting in enhanced penile erection and are used for the treatment of erectile dysfunction. Those agents, by way of vasodilator effects could interact with the systemic vasculature and could potentially affect the cardiac patient. During sexual intercourse, heart rate and blood pressure increase as with other forms of exertion. Stress to the heart during sexual intercourse is similar than that observed during other common daily activities. This article reviews the literature and provides recommendations regarding the evaluation of patients with known or suspected cardiac disease in whom therapy for erectile dysfunction is being considered. Patients who seek therapy for erectile dysfunction should undergo to individualized medical evaluation before a prescription is issued. Patients requiring therapy with long-acting nitrates should not receive prescriptions for phosphodiesterase inhibitors. Patients who are likely to develop angina with sexual exertion should not take phosphodiesterase inhibitors, as they may be tempted to take sublingual nitroglycerin. Stress testing is indicated if exercise capacity is uncertain or if significant myocardial ischemia is suspected.

Original languageEnglish (US)
Pages (from-to)291-297
Number of pages7
JournalHerz
Volume28
Issue number4
StatePublished - Jun 2003

Fingerprint

Erectile Dysfunction
Exercise
Pharmaceutical Preparations
Phosphodiesterase Inhibitors
Coitus
Prescriptions
Penile Erection
Therapeutics
Phosphodiesterase 5 Inhibitors
Cyclic GMP
Nitroglycerin
Vasodilator Agents
Nitrates
Myocardial Ischemia
Heart Diseases
Heart Rate
Blood Pressure

Keywords

  • Erectile dysfunction
  • Exercise test
  • Ischmic heart disease
  • Phosphodiesterase inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction. / Arruda-Olson, Adelaide M; Pellikka, Patricia.

In: Herz, Vol. 28, No. 4, 06.2003, p. 291-297.

Research output: Contribution to journalReview article

@article{a951920b650a4ec5b62cdf810502ce13,
title = "Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction",
abstract = "Selective inhibitors of phosphodiesterase type 5 prevent the breakdown of cyclic guanosine monophosphate resulting in enhanced penile erection and are used for the treatment of erectile dysfunction. Those agents, by way of vasodilator effects could interact with the systemic vasculature and could potentially affect the cardiac patient. During sexual intercourse, heart rate and blood pressure increase as with other forms of exertion. Stress to the heart during sexual intercourse is similar than that observed during other common daily activities. This article reviews the literature and provides recommendations regarding the evaluation of patients with known or suspected cardiac disease in whom therapy for erectile dysfunction is being considered. Patients who seek therapy for erectile dysfunction should undergo to individualized medical evaluation before a prescription is issued. Patients requiring therapy with long-acting nitrates should not receive prescriptions for phosphodiesterase inhibitors. Patients who are likely to develop angina with sexual exertion should not take phosphodiesterase inhibitors, as they may be tempted to take sublingual nitroglycerin. Stress testing is indicated if exercise capacity is uncertain or if significant myocardial ischemia is suspected.",
keywords = "Erectile dysfunction, Exercise test, Ischmic heart disease, Phosphodiesterase inhibitors",
author = "Arruda-Olson, {Adelaide M} and Patricia Pellikka",
year = "2003",
month = "6",
language = "English (US)",
volume = "28",
pages = "291--297",
journal = "Herz",
issn = "0340-9937",
publisher = "Urban und Vogel",
number = "4",

}

TY - JOUR

T1 - Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction

AU - Arruda-Olson, Adelaide M

AU - Pellikka, Patricia

PY - 2003/6

Y1 - 2003/6

N2 - Selective inhibitors of phosphodiesterase type 5 prevent the breakdown of cyclic guanosine monophosphate resulting in enhanced penile erection and are used for the treatment of erectile dysfunction. Those agents, by way of vasodilator effects could interact with the systemic vasculature and could potentially affect the cardiac patient. During sexual intercourse, heart rate and blood pressure increase as with other forms of exertion. Stress to the heart during sexual intercourse is similar than that observed during other common daily activities. This article reviews the literature and provides recommendations regarding the evaluation of patients with known or suspected cardiac disease in whom therapy for erectile dysfunction is being considered. Patients who seek therapy for erectile dysfunction should undergo to individualized medical evaluation before a prescription is issued. Patients requiring therapy with long-acting nitrates should not receive prescriptions for phosphodiesterase inhibitors. Patients who are likely to develop angina with sexual exertion should not take phosphodiesterase inhibitors, as they may be tempted to take sublingual nitroglycerin. Stress testing is indicated if exercise capacity is uncertain or if significant myocardial ischemia is suspected.

AB - Selective inhibitors of phosphodiesterase type 5 prevent the breakdown of cyclic guanosine monophosphate resulting in enhanced penile erection and are used for the treatment of erectile dysfunction. Those agents, by way of vasodilator effects could interact with the systemic vasculature and could potentially affect the cardiac patient. During sexual intercourse, heart rate and blood pressure increase as with other forms of exertion. Stress to the heart during sexual intercourse is similar than that observed during other common daily activities. This article reviews the literature and provides recommendations regarding the evaluation of patients with known or suspected cardiac disease in whom therapy for erectile dysfunction is being considered. Patients who seek therapy for erectile dysfunction should undergo to individualized medical evaluation before a prescription is issued. Patients requiring therapy with long-acting nitrates should not receive prescriptions for phosphodiesterase inhibitors. Patients who are likely to develop angina with sexual exertion should not take phosphodiesterase inhibitors, as they may be tempted to take sublingual nitroglycerin. Stress testing is indicated if exercise capacity is uncertain or if significant myocardial ischemia is suspected.

KW - Erectile dysfunction

KW - Exercise test

KW - Ischmic heart disease

KW - Phosphodiesterase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0038267649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038267649&partnerID=8YFLogxK

M3 - Review article

C2 - 12825144

AN - SCOPUS:0038267649

VL - 28

SP - 291

EP - 297

JO - Herz

JF - Herz

SN - 0340-9937

IS - 4

ER -